CD8A and neoplasm: For example, in two subsequent independent vaccination studies, autologous tumor ApoBD-pulsed dendritic cells appeared to trigger a leukemia-specific CD8+ T-cell response, T-cell–tumor cell aggregation, and reduced regulatory T-cell levels in 40–60% of the patient cohorts, without dose-limiting toxicity and autoimmunity, however, clinical trials of these effects are lacking, which warrants further studies (Palma et al., 2012).